Regardless of the cause of a disease, most diseases involve gene dysregulation. Omega Therapeutics is developing a new class of programmable, epigenomic, mRNA medicines designed to make specific epigenetic changes and correct abnormal gene expression to treat or cure diseases. We spoke to Mahesh Karande, president and CEO of Omega Therapeutics, about its pipeline of mRNA therapies, how they work, and its recently announced collaboration with Novo Nordisk to develop an epigenomic controller to treat obesity.
Bringing Stick-to-itiveness to Regenerative Medicine
A Biopharma Downturn or Return to Trend
Treating Aging-Related Disease by Targeting Molecular Drivers of Aging
Engineering Better Cell Therapies for Cancers
Targeting a Regulator of Inflammation to Treat Alzheimer’s Disease
Enabling Regenerative Therapies without Immunosuppression
Making Vaccine and Biotherapeutic Production Fast and Affordable
Forcing Cancers to Reveal Themselves
Making Clinical Trials Diverse and Accessible
Mining Bugs for Drugs
A Company That Bets Its Therapies Will Click with Patients
A Company Where It takes Guts and Brains to Develop Drugs
Changing Outcomes with Data
Treating Psychiatric Conditions with Tripless Psychedelics
How AI Is Finding Its Way into Unexpected Places in Biopharma Companies
Searching the Dark Matter of the Proteome to Develop New Therapies
The Year in Biotech and What’s Ahead in 2023
Targeting a Novel Checkpoint to Treat Cancer and Autoimmune Conditions
The Growing Need for Biosecurity Vigilance
Enlisting Next-Generation Cytokine Immunotherapies in the Fight Against Cancer
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Stuff To Blow Your Mind
Unexplainable
Ground Truths